Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of expediting a NICE appraisal for Givinostat.

The National Institute for Health and Care Excellence (NICE) works with companies on timelines for its evaluations of new medicines, and aims, wherever possible, to issue guidance close to the point of licensing to support rapid access for National Health Service patients to clinically and cost-effective medicines. The NICE’s timeline for its evaluation of givinostat was rescheduled at the request of the company, to facilitate a suitably comprehensive and robust submission. The NICE’s Appraisal Committee is due to meet to consider its recommendations on givinostat in May 2025.